Get the Stockscreener App
323.07
0.56%
1.80
Insulet Corporation stock is traded at $323.07, with a volume of 457.80K.
It is up +0.56% in the last 24 hours and up +13.66% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
See More
Previous Close:
$321.27
Open:
$321.32
24h Volume:
457.80K
Relative Volume:
0.62
Market Cap:
$22.74B
Revenue:
$2.20B
Net Income/Loss:
$402.20M
P/E Ratio:
58.11
EPS:
5.56
Net Cash Flow:
$280.80M
1W Performance:
+5.98%
1M Performance:
+13.66%
6M Performance:
+15.09%
1Y Performance:
+66.95%
1-Day Range:
$320.75
$323.83
1-Week Range:
$302.41
$323.83
52-Week Range:
$180.31
$329.33
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
323.07 | 22.62B | 2.20B | 402.20M | 280.80M | 5.56 |
|
ABT
Abbott Laboratories
|
130.27 | 229.31B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.05 | 152.87B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.61 | 146.01B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.81 | 119.18B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.30 | 45.95B | 5.69B | 1.41B | 577.90M | 6.95 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Insulet to Participate in Upcoming Investor Conferences - Business Wire
Insulet Corporation : There is still some upside potential - MarketScreener
Is Insulet Corporation subject to activist investor interest2025 Market WrapUp & AI Powered Trade Plan Recommendations - thegnnews.com
Insulet’s (PODD) Aggressive Revenue Guidance and Buyback Might Change the Case for Investing - simplywall.st
Published on: 2025-08-16 12:18:14 - sundaytimes.kr
Insulet Shares Soar on Volume Surge as Stock Ranks 495th in Market Activity for the Day - AInvest
Quant Strategy Flags Insulet Corporation for EntryJuly 2025 Catalysts & High Accuracy Trade Signal Alerts - newsyoung.net
Short Covering May Lift Insulet Corporation in Near TermQuarterly Profit Review & Weekly High Return Opportunities - sundaytimes.kr
Stock Market Today: Indexes Hold Strong, But Small Caps Lag; Netflix, Amazon, Insulet In Focus - Investor's Business Daily
There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings - simplywall.st
Insulet's (NASDAQ:PODD) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
Investors Can Find Comfort In Insulet's (NASDAQ:PODD) Earnings Quality - 富途牛牛
The Top 5 Analyst Questions From Insulet’s Q2 Earnings Call - Yahoo Finance
Insulet’s Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold (PODD) - Seeking Alpha
Elliott Wave Theory Predicts Pullback in Insulet CorporationEarnings Miss & Intraday High Probability Setup Alerts - beatles.ru
Sapiens International Q2 Earnings Decline, Revenue Rises Amid Acquisition Deal - AInvest
PODD Q2 Deep Dive: Omnipod 5 Adoption and International Expansion Drive Results - Yahoo Finance
Insulet Rises to 470th in Trading Volume as Q2 Revenue Surges 32.9 and Margins Expand - AInvest
Insulet Q2 Earnings and Revenue Exceed Estimates, Stock Rises, Margins Improve - AInvest
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise - TradingView
Insulet Corporation Reports Strong Q2 2025 Growth - MSN
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - sharewise.com
Insulet Corp: Strong Financial Position and Competitive Strengths - AInvest
Why Insulet (PODD) Is Up 7.8% After Raising Full-Year Revenue Guidance on Omnipod Momentum - simplywall.st
Is It Too Late to Sell Insulet CorporationLow Drawdown Real Time Trading Tips Shared - beatles.ru
Price Consolidation Hints at Upcoming Move in Insulet CorporationFast Exit and Entry Strategy Guide Offered - beatles.ru
Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN
Insulet's Insider Activity and Executive Compensation Transparency: A Governance and Investor Sentiment Analysis - AInvest
Insulet’s Earnings Call Highlights Robust Growth and Optimism - The Globe and Mail
Research Alert: CFRA Maintains Hold Opinion On Shares Of Insulet Corporation - 富途牛牛
RBC Capital Raises PT for Insulet to $350, Maintains Outperform Rating - AInvest
Insulet Corporation shares rise 2.61% intraday after multiple brokerages raised price targets. - AInvest
Insulet (PODD) Is Up 5.3% After Raising Full-Year Revenue Guidance on Strong Q2 Sales – Has The Bull Case Changed? - simplywall.st
Baird Adjusts Price Target on Insulet to $360 From $350, Maintains Outperform Rating - MarketScreener
Insulet stock price target raised to $350 from $330 at RBC Capital - Investing.com Canada
Bernstein raises Insulet stock price target to $400 on type 2 diabetes growth - Investing.com Nigeria
RBC Raises Price Target on Insulet to $350 From $330, Keeps Outperform Rating - MarketScreener
Insulet price target raised to $350 from $330 at RBC Capital - TipRanks
Insulet Corporation (PODD) PT Raised to $350 at RBC Capital - StreetInsider
Insulet Corporation (NASDAQ:PODD) Q2 2025 Earnings Call Transcript - Insider Monkey
Insulet Corporation (PODD) PT Raised to $400 at Bernstein SocGen Group - StreetInsider
Insulet price target raised to $353 from $331 at Canaccord - TipRanks
Morgan Stanley Raises Price Target on Insulet to $370 From $355, Keeps Overweight Rating - MarketScreener
Goldman Sachs Adjusts Price Target on Insulet to $399 From $380, Maintains Buy Rating - MarketScreener
Canaccord Genuity Adjusts Price Target on Insulet to $353 From $331, Maintains Buy Rating - MarketScreener
Bernstein Adjusts Price Target on Insulet to $400 From $375, Maintains Outperform Rating - MarketScreener
Tandem, Insulet monitoring CMS payment proposal for diabetes tech - Yahoo Finance
Insulet: Q2 Earnings Snapshot - Connecticut Post
Insulet raises full-year 2025 revenue growth guidance to 24%-27% as Omnipod 5 drives global adoption - MSN
Insulet Corp (PODD) Q2 2025 Earnings Call Highlights: Record Revenue and Raised Guidance Amid ... By GuruFocus - Investing.com Canada
Insulet Corp. stock outperforms competitors on strong trading day - MSN
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):